Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · As of May 2026 — confirm current pricing directly with the pharmacy or manufacturer.
Key Takeaways
- Cash retail Zepbound pen: ~$1,059/month. Lilly Direct vials: $349 to $499/month. The vial program is the cheapest brand-name path for uninsured patients
- The standard Zepbound savings card does not apply without commercial insurance; the right Lilly program for uninsured patients is Lilly Cares (free for qualifying patients)
- Annual brand cost ranges from approximately $4,188 to $12,708 depending on format and dose
- Compounded tirzepatide from a 503A pharmacy typically runs $299 to $549 monthly, but is not FDA-approved or interchangeable with Zepbound
- Personal importation carries seizure, counterfeit, and cold-chain risk; the savings are real but the tradeoffs are too
Direct answer
Cash-pay Zepbound in May 2026 has two real prices: roughly $1,059 per month for the pen at U.S. retail, or $349 to $499 per month through Lilly Direct's manufacturer-direct vial program. Uninsured patients should default to Lilly Direct vials unless they cannot self-inject from a syringe. Patients with incomes at or below 400% of the federal poverty level should apply to Lilly Cares for free medication. Compounded tirzepatide at a 503A pharmacy is a separate legal product at $299-$549 monthly. Confirm current pricing directly with the pharmacy or manufacturer.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- What "uninsured" really means at the Zepbound counter
- The pen retail price, then and now
- Lilly Direct: the manufacturer-built cash-pay option
- Lilly Cares for low-income uninsured patients
- What the savings card does (and does not do) for cash patients
- Year-over-year cost projections
- Compounded tirzepatide as a cash alternative
- The international tirzepatide question
- Decision framework for cash-pay Zepbound
- What we see on the FormBlends platform
- FAQ
- Sources
What "uninsured" really means at the Zepbound counter
Three groups of patients hear the same answer when they ask "how much without insurance?" but each has different best options:
- Truly uninsured: no health plan. Best access via Lilly Direct vials or Lilly Cares
- Insured but plan excludes anti-obesity medications: a common scenario. The savings card may offer a modest discount on the pen; Lilly Direct vials are usually cheaper
- Insured but in pre-deductible territory: paying full negotiated rate (~$700 to $900 per month) until deductible meets. Lilly Direct vials often beat this until the deductible clears
The Lilly Direct portal does ask about insurance status, but vial purchases do not require uninsured certification. Many patients with coverage that excludes Zepbound use Lilly Direct vials as their primary access route.
The pen retail price, then and now
Brand Zepbound launched in late 2023 at a list price near $1,059 monthly for the pen, deliberately below Wegovy's $1,349. The wholesale acquisition cost has held steady since. Cash retail quotes in May 2026 cluster between $1,020 and $1,095 depending on the pharmacy. Costco member pricing tends to sit slightly below national chain averages. Confirm current pricing directly with the pharmacy or manufacturer.
A one-month supply is four single-use autoinjector pens, one weekly dose each. There is no half-month or weekly dispensing option for the pen.
Lilly Direct: the manufacturer-built cash-pay option
Lilly opened Lilly Direct in mid-2024 specifically to capture cash-pay demand at a lower price point than the pen. The program offers tirzepatide in single-dose vial format, shipped directly from a Lilly-contracted pharmacy.
Vial pricing in May 2026:
| Dose | Monthly cost | Annual cost |
|---|---|---|
| 2.5 mg (titration) | $349 | ~$4,188 |
| 5 mg | $499 | ~$5,988 |
| 7.5 mg | $499 | ~$5,988 |
| 10 mg | Per current Lilly Direct posting | Higher |
| 12.5 mg | Per current Lilly Direct posting | Higher |
| 15 mg | Per current Lilly Direct posting | Higher |
The order includes the vials, syringes, and needles. Shipping is free. Patients ordering through the platform need a prescription specifically for the vial NDC, which is different from the pen NDC.
The technique tradeoff: vials require drawing the dose into a syringe and self-injecting. Lilly Direct provides instructional materials. Patients comfortable with injections typically learn the technique within one or two doses. Patients with manual dexterity issues, vision problems, or strong needle anxiety often find the vial more difficult and may prefer to pay pen pricing if they can.
Lilly Cares for low-income uninsured patients
The Lilly Cares Foundation Patient Assistance Program provides Zepbound at no cost to qualifying uninsured U.S. residents. Criteria:
- U.S. residency
- Household income at or below 400% of the federal poverty level (~$60,240 single, ~$124,800 family of four in 2026)
- Uninsured, or insured without prescription drug coverage that includes Zepbound
- Prescription for an FDA-approved Zepbound indication (chronic weight management with BMI 30+ or 27+ with comorbidity; or moderate-to-severe OSA with obesity)
The application is submitted by the prescriber with financial documentation. Approval typically takes four to eight weeks. Approved patients receive shipments directly. Renewals require updated income documentation annually.
Most rejections trace to incomplete income documentation or coverage status that does not match the form. Plans that "exclude" Zepbound but technically include other prescription drug coverage can sometimes complicate eligibility.
What the savings card does (and does not do) for cash patients
The Zepbound Savings Card on Zepbound.lilly.com has two flavors:
- With insurance that covers Zepbound: copays as low as $25 per month, subject to savings caps
- With insurance that does not cover Zepbound: discounted price on the pen, often around $650 monthly, subject to annual cap
What it does not do: it does not apply to uninsured patients. The card requires a commercial insurance ID at activation. Patients without insurance attempting to use the card will be told they are not eligible.
For uninsured patients trying to access Zepbound via the savings card, the workaround does not exist. The right path is Lilly Direct vials (or Lilly Cares for income-eligible patients).
Year-over-year cost projections
Out-of-pocket annual cost depends on format, dose, and program:
| Path | Approximate monthly cost | Approximate annual cost |
|---|---|---|
| Pen at cash retail | $1,059 | $12,708 |
| Pen with savings card (insurance doesn't cover) | ~$650 | ~$7,800 |
| Lilly Direct 5 mg vials | $499 | $5,988 |
| Lilly Direct 2.5 mg vials (titration only) | $349 | $4,188 |
| Lilly Cares (if approved) | $0 | $0 |
| Compounded tirzepatide via 503A | $299-$549 | $3,588-$6,588 |
Most patients on the maintenance dose (10 mg, 12.5 mg, or 15 mg) eventually face higher Lilly Direct vial pricing than the 5 mg starter. Even at the highest tier, vial pricing remains well below the pen.
Compounded tirzepatide as a cash alternative
Compounded tirzepatide is the most common reason patients choose not to use Lilly Direct. The price difference between $499 vial and $299 compounded is meaningful for many budgets. The tradeoff is regulatory:
- Compounded tirzepatide is prepared by 503A state-licensed compounding pharmacies in response to specific prescriptions
- It is not FDA-approved and has not been through the FDA's drug review process
- Compounded products are not interchangeable with brand Zepbound; concentration, vehicle, and bioavailability can differ
- The FDA's compounding regulations and the ongoing shortage list status of tirzepatide have shifted multiple times since 2023
Patients considering compounded tirzepatide should confirm the pharmacy is 503A (not 503B unless specifically explained), licensed in the state of dispensing, and operating in a state with active board oversight. Reputable telehealth platforms work with named, transparent pharmacy partners.
FormBlends partners with 503A pharmacies for compounded semaglutide and tirzepatide programs with published transparent pricing.
The international tirzepatide question
Outside the U.S., tirzepatide is generally sold under the Mounjaro name (Lilly markets the obesity indication under Mounjaro in many countries rather than launching Zepbound separately). Personal importation of Mounjaro from Canadian or European pharmacies is technically a gray area under FDA enforcement.
The savings can be substantial (international list prices for tirzepatide are often 50 to 75 percent below U.S. retail), but the risks include:
- Customs seizure of personal-use quantities, though enforcement has historically been light
- Counterfeit product, particularly from non-accredited sellers
- Cold-chain failures during international shipping
- Lack of U.S. clinical and pharmacy oversight in the event of an adverse reaction
Given Lilly Direct's vial pricing, the international option has become less compelling than it once was. Lilly Direct 5 mg at $499 is comparable to or below many international personal-importation paths, with full U.S. regulatory backing.
Decision framework for cash-pay Zepbound
Run through these in order:
Step 1: If your household income is at or below 400% of FPL and you are uninsured, apply to Lilly Cares first. Approval = $0.
Step 2: While waiting on Lilly Cares, or if you do not qualify, use Lilly Direct vials. Manufacturer-direct, FDA-approved, $349-$499.
Step 3: If you cannot self-inject from a vial, the pen with the savings card (insurance-doesn't-cover tier, ~$650) is the next-cheapest brand option.
Step 4: Compounded tirzepatide via a reputable 503A telehealth platform is the cheapest legal path overall, with the regulatory caveats above.
Step 5: Personal importation is a last resort given Lilly Direct's pricing. The savings rarely justify the risks now.
What we see on the FormBlends platform
Uninsured patients asking about Zepbound divide into recognizable groups:
About 30 percent qualify for Lilly Cares and end up paying $0 after a four-to-eight-week wait. We help them bridge with compounded tirzepatide if they need to start immediately.
About 40 percent choose Lilly Direct vials. They want the FDA-approved brand, can self-inject from a vial, and can absorb $349-$499 monthly.
About 25 percent choose compounded tirzepatide. Lower cost, faster start, accept the regulatory tradeoff.
The remaining 5 percent stay on pen retail because of inability to use vials and unwillingness to switch to compounded. Their monthly cost is the highest in the cohort.
FAQ
How much is Zepbound without insurance in 2026? About $1,059 per month for the pen at cash retail; $349 to $499 per month through Lilly Direct vials.
Can uninsured patients use the Zepbound savings card? No. The card requires commercial insurance. Lilly Direct vials and Lilly Cares are the manufacturer-supported uninsured paths.
What is the cheapest legitimate way to buy Zepbound without insurance? Lilly Cares for income-eligible patients ($0). Lilly Direct vials for everyone else ($349-$499).
Is compounded tirzepatide a legitimate alternative to brand Zepbound? When prepared by a 503A state-licensed pharmacy under an individual prescription, yes. It is not FDA-approved and not interchangeable with brand Zepbound.
Does Lilly Direct deliver to all 50 states? Yes, including Washington D.C.
How much will Zepbound cost over a year without insurance? $4,188 to $12,708 depending on format and dose.
Is paying cash for Zepbound a reasonable choice? For appropriate indications and a budget that can absorb Lilly Direct pricing, yes. For tighter budgets, compounded alternatives merit consideration.
Can I buy Zepbound from outside the United States? Personal importation exists in a gray area with seizure, counterfeit, and cold-chain risks. Lilly Direct pricing has made this less attractive than it was.
Can a telehealth platform offer Zepbound at a discount? Telehealth platforms generally cannot beat Lilly Direct vial pricing for brand Zepbound. Their cost advantage typically comes from compounded tirzepatide programs.
What happens if I cannot afford to continue Zepbound? Discontinuation tends to result in weight regain over the following 6 to 12 months based on SURMOUNT-4 maintenance data. Plan transitions or compounded alternatives before stopping cold turkey.
Will Lilly Direct prices increase over time? Lilly Direct vial pricing has trended down slightly since the program launched in 2024. Manufacturer policy can change; check Lilly Direct's current rate before each order.
Sources
- Eli Lilly and Company. Zepbound and Lilly Direct program documentation. LillyDirect.com. 2026.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. 2024.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022 (SURMOUNT-1).
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024 (SURMOUNT-4).
- U.S. Department of Health and Human Services. Federal Poverty Level Guidelines 2026. ASPE.
- FDA. Personal Importation Policy. Regulatory Procedures Manual.
- Lilly Cares Foundation. Patient assistance program documentation. 2026.
- Kaiser Family Foundation. Employer Health Benefits Survey 2025. GLP-1 coverage section.
- USP. Standards for Compounded Sterile Preparations (USP 797). 2023.
- FDA. Drug Shortages Database. Tirzepatide listings 2023-2025.
- NeedyMeds. Lilly Cares and patient assistance program directory. 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and partnered pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are the responsibility of the treating provider.
Compounded Medication Notice. Compounded tirzepatide referenced in this article is prepared by 503A state-licensed compounding pharmacies in response to specific prescriptions. These preparations have not been reviewed by the FDA for safety, efficacy, or manufacturing quality and are not generic equivalents to brand Zepbound.
Results Disclaimer. Dollar figures cited reflect public manufacturer, retail, and program data available in May 2026. Lilly Direct pricing, Lilly Cares eligibility, and manufacturer programs change on their own schedules. Confirm current pricing with the manufacturer or pharmacy.
Trademark Notice. Zepbound, Mounjaro, Lilly Direct, and Lilly Cares are registered trademarks of Eli Lilly and Company. Other brand names referenced are property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →